{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:22:27Z","timestamp":1788013347348,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejca.2024.113921","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T07:11:16Z","timestamp":1707981076000},"page":"113921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries"],"prefix":"10.1016","volume":"201","author":[{"given":"Niels","family":"Abildgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-0657","authenticated-orcid":false,"given":"Pekka","family":"Anttila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9072-1220","authenticated-orcid":false,"given":"Anders","family":"Waage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine Hass","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"\u00d8rstavik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal","family":"Bent-Ennakhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Gavini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3602-4189","authenticated-orcid":false,"given":"Jonatan","family":"Freilich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-4548","authenticated-orcid":false,"given":"Markus","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2024.113921_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2019.09.625","article-title":"Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed\/refractory multiple myeloma","volume":"20","author":"Chari","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.ejca.2024.113921_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020407","article-title":"Multiple myeloma: available therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ejca.2024.113921_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ejca.2024.113921_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106219","article-title":"Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan","volume":"85","author":"Weil","year":"2019","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.ejca.2024.113921_bib5","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.113921_bib6","article-title":"Multiple myeloma: an overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat Care Soc Pr"},{"issue":"2","key":"10.1016\/j.ejca.2024.113921_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.ejca.2024.113921_bib8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ejca.2024.113921_bib9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3324\/haematol.2017.178103","article-title":"Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry","volume":"103","author":"Blimark","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.ejca.2024.113921_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208507","article-title":"Real-world treatment outcomes in multiple myeloma: multicenter registry results from Finland 2009-2013","volume":"13","author":"Remes","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejca.2024.113921_bib11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ejh.13439","article-title":"Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple myeloma in France, Germany, Italy, and the United Kingdom","volume":"105","author":"Mohty","year":"2020","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.ejca.2024.113921_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/ejh.13581","article-title":"Patterns of previous and secondary malignancies in patients with multiple myeloma","volume":"106","author":"Langseth","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejca.2024.113921_bib13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2147\/CLEP.S413587","article-title":"Use of linked Nordic registries for population studies in haematological cancers: the case of multiple myeloma","volume":"15","author":"Abildgaard","year":"2023","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ejca.2024.113921_bib14","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2147\/CLEP.S99463","article-title":"The Danish national multiple myeloma registry","volume":"8","author":"Gimsing","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.ejca.2024.113921_bib15","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/ijc.27462","article-title":"Comparability of cancer identification among death registry, cancer registry and hospital discharge registry","volume":"131","author":"Ji","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2024.113921_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2017.02.017","article-title":"Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours","volume":"77","author":"Leinonen","year":"2017","journal-title":"Eur J Cancer"},{"issue":"17_suppl","key":"10.1016\/j.ejca.2024.113921_bib17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1403494817702336","article-title":"Nordic registry-based cohort studies: Possibilities and pitfalls when combining Nordic registry data","volume":"45","author":"Maret-Ouda","year":"2017","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.ejca.2024.113921_bib18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/CLEP.S314959","article-title":"Nordic health registry-based research: a review of health care systems and key registries","volume":"13","author":"Laugesen","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ejca.2024.113921_bib19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/bjh.14193","article-title":"Multiple myeloma: practice patterns across Europe","volume":"175","author":"Raab","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2024.113921_bib20","unstructured":"Nordic Myeloma Study Group (NMSG). Recommendations for allogeneic haematopoietic stem cell transplantation of multiple myeloma. On behalf of NMSG. Available from: \u3008http:\/\/www.nordic-myeloma.org\/filer\/Referenceprogrammer\/Annette_Vangsted_MM_allo_Nordic_recommendations-marts2017\u20133.pdf\u3009. (accessed 6 November 2021)."},{"issue":"10","key":"10.1016\/j.ejca.2024.113921_bib21","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN guidelines insights: multiple myeloma, version 1.2020","volume":"17","author":"Kumar","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2024.113921_bib22","unstructured":"Boccadoro M., Usmani S.Z., Chari A., et al. A global treatment standard in multiple myeloma (MM) remains elusive despite advances in care over 15 years: first results from INSIGHT MM, the largest global prospective, observational MM study. Preliminary data from the first 1000 patients enrolled in the INSIGHT MM study from 13 countries. Presented at: 23rd Congress of the European Hematology Association; 14\u201317 June 2018; Stockholm, Sweden."},{"key":"10.1016\/j.ejca.2024.113921_bib23","doi-asserted-by":"crossref","unstructured":"Usmani S.Z., Hungria V.T.M., Xavier Leleu X., et al. Transplant status does not impact the selection of induction regimens for newly diagnosed multiple myeloma (NDMM) patients (pts) in the INSIGHT MM prospective, observational study. Preliminary data from the first 1056 patients with newly diagnosed MM enrolled in the INSIGHT MM study from 14 countries. Presented at: American Society of Hematology 60th Annual Meeting & Exposition; 1\u20134 December 2018; San Diego, CA, USA.","DOI":"10.1182\/blood-2018-99-112846"},{"issue":"7","key":"10.1016\/j.ejca.2024.113921_bib24","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"10068","key":"10.1016\/j.ejca.2024.113921_bib25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejca.2024.113921_bib26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejca.2024.113921_bib27","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ejca.2024.113921_bib28","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1080\/10428194.2021.1924369","volume":"62","author":"Zamagni","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.ejca.2024.113921_bib29","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:54Z","timestamp":1760733834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":29,"alternative-id":["S0959804924000972"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113921","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113921"}}